Techniclone International Corp. announced Tuesday that AlphaTherapeutic Corp. has filed an investigational new drug (IND)application with FDA for a Phase III clinical trial ofTechniclone's131-Iodine/LYM-1 monoclonal antibody inpatients who have non-Hodgkin's B-cell lymphoma.
Alpha Therapeutic of Los Angeles, which is sponsoring the IND,has licensed the marketing rights to LYM-1 (to be trade-namedOncolym) in the U.S. and other parts of the world. Technicloneof Tustin, Calif., retains manufacturing rights and will supplythe antibody for both the trials and commercial use if the drugis approved for marketing.
(c) 1997 American Health Consultants. All rights reserved.